Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: abiomed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $235.00 → $380.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/2/2022 | $355.00 → $388.00 | Buy → Hold | Deutsche Bank |
| 10/13/2022 | $300.00 | Buy | Mizuho |
| 4/6/2022 | $330.00 | Peer Perform | Wolfe Research |
| 2/4/2022 | $292.00 → $275.00 | Underweight | Morgan Stanley |
| 2/4/2022 | $345.00 → $325.00 | Market Perform | SVB Leerink |
| 1/7/2022 | $269.00 → $292.00 | Underweight | Morgan Stanley |
| 8/6/2021 | $335.00 → $375.00 | Market Perform | SVB Leerink |
| 7/20/2021 | $355.00 → $335.00 | Market Perform | SVB Leerink |
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion
Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. ("Offeror"), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the "Offer") to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ:ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The Offer, which was previously scheduled to expire at 11:59 p.m., New York City time, on December 13, 2022, has been extende
Abiomed (NASDAQ:ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005137/en/Impella RP Flex with SmartAssist Illustration (Graphic: Business Wire) Impell
CHELMSFORD, Mass., Nov. 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Tina S. Nova, Ph.D. and Dorothy E. Puhy have been nominated for election to its Board of Directors at the Company's 2023 Annual General Meeting. They will join as non-voting observers of the Company's Board of Directors with immediate effect. "We are fortunate to have candidates of the caliber of Tina and Dorothy for Azenta's Board," said Steve Schwartz, President and CEO. "They will bring tremendous life sciences experience to our Board and are proven value-creators in the space. Their perspectives will be invaluable as Azenta continues to expand and evolve as a leading life sciences company." J
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa
Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil
Abiomed (NASDAQ:ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA's highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and has dual-sensor technology designed to optimize patient management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005234/en/Impella RP Flex with SmartAssist (Photo: Business Wire) The Impella RP platform includes the world's smallest percutaneous right heart mechani
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support Abiomed (NASDAQ:ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients. Data from a subgroup analysis of 93 non-Caucasian high-risk PCI patients enrolled in the PROTECT II Randomized Controlled Trial (RCT) finds those who were treated with Abiomed's Impella heart pump had significantly improved clinical outcomes compared to those who were treated with the intra-aortic balloon pump (
15-12G - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)
S-8 POS - ABIOMED INC (0000815094) (Filer)